Exponent, Inc. (NASDAQ:EXPO – Get Free Report) VP Richard Reiss sold 1,280 shares of the company’s stock in a transaction on Tuesday, November 3rd. The shares were sold at an average price of $86.44, for a total value of $110,643.20. Following the transaction, the vice president directly owned 1,008 shares in the company, valued at $87,131.52. This represents a 55.94% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.
Exponent Stock Performance
EXPO stock opened at $85.83 on Friday. The company has a market capitalization of $4.08 billion, a price-to-earnings ratio of 37.00 and a beta of 0.66. Exponent, Inc. has a fifty-two week low of $51.91 and a fifty-two week high of $90.51. The stock has a fifty day moving average of $71.48 and a 200-day moving average of $66.90.
Exponent (NASDAQ:EXPO – Get Free Report) last announced its quarterly earnings data on Thursday, October 29th. The business services provider reported $0.64 earnings per share for the quarter, topping the consensus estimate of $0.60 by $0.04. Exponent had a return on equity of 34.61% and a net margin of 17.40%. The company had revenue of $173.73 million during the quarter, compared to analyst estimates of $149.64 million. During the same quarter last year, the firm posted $0.55 EPS. The firm’s revenue for the quarter was up 11.7% on a year-over-year basis. Equities analysts predict that Exponent, Inc. will post 2.36 EPS for the current year.
Exponent Announces Dividend
The firm also recently announced a quarterly dividend, which will be paid on Friday, December 18th. Shareholders of record on Friday, December 4th will be given a dividend of $0.31 per share. This represents a $1.24 dividend on an annualized basis and a yield of 1.4%. The ex-dividend date is Friday, December 4th. Exponent’s dividend payout ratio (DPR) is currently 53.45%.
Analyst Upgrades and Downgrades
Several research firms have recently issued reports on EXPO. Zacks Research raised shares of Exponent from a “hold” rating to a “strong-buy” rating in a research report on Monday. UBS Group raised their price objective on shares of Exponent from $72.00 to $82.00 and gave the stock a “neutral” rating in a report on Friday, October 30th. Weiss Ratings upgraded shares of Exponent from a “hold (c-)” rating to a “hold (c)” rating in a research note on Friday, October 9th. Finally, JPMorgan Chase & Co. boosted their target price on shares of Exponent from $90.00 to $100.00 and gave the company an “overweight” rating in a report on Friday, October 30th. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat, Exponent has an average rating of “Moderate Buy” and a consensus target price of $91.00.
Get Our Latest Analysis on Exponent
Institutional Inflows and Outflows
Several large investors have recently added to or reduced their stakes in the stock. Hohimer Wealth Management LLC bought a new stake in shares of Exponent during the 3rd quarter valued at about $221,000. Summit Creek Advisors LLC purchased a new position in shares of Exponent during the third quarter worth about $2,520,000. Chicago Partners Investment Group LLC purchased a new position in shares of Exponent during the third quarter worth about $226,000. Covestor Ltd grew its holdings in shares of Exponent by 10.3% during the third quarter. Covestor Ltd now owns 2,050 shares of the business services provider’s stock worth $134,000 after purchasing an additional 192 shares in the last quarter. Finally, Bridge City Capital LLC grew its holdings in shares of Exponent by 21.6% during the third quarter. Bridge City Capital LLC now owns 49,231 shares of the business services provider’s stock worth $3,221,000 after purchasing an additional 8,729 shares in the last quarter. Institutional investors own 92.37% of the company’s stock.
Exponent Company Profile
Exponent, Inc is a science and engineering consulting company that helps clients investigate complex technical issues, manage risks, and develop solutions. Its consultants work across disciplines including engineering, materials science, biomechanics, human factors, environmental science, health, data sciences, and economics.
The company provides failure analysis, product safety and testing, accident reconstruction, environmental and health assessments, regulatory support, and expert testimony.
Featured Articles
- Five stocks we like better than Exponent
- Google’s Credit Backstop May Be TeraWulf’s Biggest Advantage
- Could the Midterms Revive Medicare for All? 3 Healthcare Stocks to Watch
- Qualcomm Beat Earnings, But Its Fastest-Growing Businesses Have a Catch
- Oil, Uranium, or Renewables? 3 Energy Plays for a Changing Market
Receive News & Ratings for Exponent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exponent and related companies with MarketBeat.com's FREE daily email newsletter.
